Trials / Recruiting
RecruitingNCT04748601
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Upsher-Smith Laboratories · Industry
- Sex
- All
- Age
- 6 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qudexy XR | Extended-Release Capsule |
| DRUG | Placebo | Qudexy XR Matching capsules |
Timeline
- Start date
- 2021-02-19
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2021-02-10
- Last updated
- 2025-01-27
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04748601. Inclusion in this directory is not an endorsement.